Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2012 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - mars 2012

Laquinimod - registreringsansökan planeras inlämnas i EU andra halvåret 2012 - fas III-data presenterade på "64th Annual Meeting of the American Academy of Neurology"...
April 26, 2012 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January - March 2012

Laquinimod - submission of application for regulatory approval in the EU planned for second half of 2012 - Phase III data presented at the Annual Meeting of the American Academy of...
April 17, 2012 04:00 ET | Source: Active Biotech

Årsredovisning 2011 Active Biotech AB (publ)

Active Biotechs årsredovisning för 2011 finns nu tillgänglig på www.activebiotech.com. Årsredovisningen kommer enbart att distribueras digitalt. Lund den 17 april 2012Active Biotech AB (publ) ...
April 17, 2012 04:00 ET | Source: Active Biotech

Annual Report 2011 Active Biotech AB (publ)

Active Biotech's Annual Report 2011 (in Swedish) is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Lund, April 17, 2012 Active...
April 11, 2012 02:30 ET | Source: Active Biotech

Active Biotech: Kallelse till årsstämma

Styrelsen för Active Biotech AB (publ) har utfärdat kallelse till årsstämma, vilken kommer äga rum torsdagen den 10 maj 2012 klockan 17.00 på Edison Park, Emdalavägen 16 i Lund. Kallelsen, som...
April 11, 2012 02:30 ET | Source: Active Biotech

Active Biotech: Notice of Annual General Meeting of Shareholders

The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 10, 2012, at Edison Park, Emdalavägen 16 in...
March 15, 2012 08:00 ET | Source: Active Biotech

Fas III-studien med Tevas orala laquinimod publicerad i The New England Journal of Medicine påvisar den kliniska nyttan för patienter med multipel skleros

Fas III-studien ALLEGRO visar att laquinimod minskar antalet relapser per år, bromsar sjukdomsutvecklingen och minskar förlusten av hjärnvävnad Laquinimod uppvisar en fördelaktig säkerhets-...
March 15, 2012 08:00 ET | Source: Active Biotech

Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients

Phase III ALLEGRO study results showed laquinimod reduced the annual rate of relapses, slowed the progression of disability, and decreased brain tissue loss Laquinimod was associated with...
February 24, 2012 02:30 ET | Source: Active Biotech

Active Biotech och Ipsen presenterar på konferensen 27th European Association of Urology (EAU) för första gången långtidssäkerhetsdata från fas II-studien av tasquinimod (TASQ)

Lund och Paris den 24 februari, 2012 - Active Biotechs (NASDAQ OMX NORDIC: ACTI) och Ipsens (Euronext: IPN; ADR: IPSEY) projekt för behandling av kastratresistent prostatacancer, TASQ, kommer att...
February 24, 2012 02:30 ET | Source: Active Biotech

Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress

Lund (Sweden) and Paris (France), February 24, 2012 - Active Biotech's (NASDAQ OMX NORDIC: ACTI) and Ipsen's (Euronext: IPN; ADR: IPSEY) castrate resistant prostate cancer project, TASQ will be...